Protecting against ischemia-reperfusion injury

Antiplatelet drugs, statins, and their potential interactions

Yumei Ye, Jose R. Perez-Polo, Yochai Birnbaum

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Statins and antiplatelet agents are currently used as therapeutic agents for patients with acute myocardial infarction. Statins limit myocardial infarct size by activating phosphatidylinositol-3-kinase (PI3K), ecto-5'-nucleotidase, Akt/endothelial nitric oxide synthase (eNOS), and the downstream effectors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Inhibition of PI3K, adenosine receptors, eNOS, iNOS, or COX-2 abrogates the protective effects of statins. At >5 mg/kg, aspirin attenuates the myocardial infarct-size-limiting effect of statins. In contrast, the combination of low-dose atoravastatin with either the phosphodiesterase-III inhibitor cilostazol or the adenosine reuptake inhibitor dipyridamole synergistically limits infarct size. Low-dose aspirin with dipyridamole started during ischemia augmented the infarct-size-limiting effects of simvastatin. In contrast, high-dose aspirin blocked the protective effect of simvastatin. The combination of dipyridamole with low-dose aspirin and simvastatin resulted in the smallest infarct size. According to themost current data available, we believe that antiplatelet regimens may require modification for patients who are receiving statins.

Original languageEnglish (US)
Pages (from-to)76-82
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume1207
DOIs
StatePublished - 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Platelet Aggregation Inhibitors
Reperfusion Injury
Aspirin
Simvastatin
Dipyridamole
Phosphatidylinositol 3-Kinase
Nitric Oxide Synthase Type III
Myocardial Infarction
Nitric Oxide Synthase Type II
Cyclooxygenase 2
Type 3 Cyclic Nucleotide Phosphodiesterases
5'-Nucleotidase
Purinergic P1 Receptors
Phosphodiesterase Inhibitors
Proxy
Adenosine
Ischemia
Drugs
Interaction

Keywords

  • Antiplatelet agents
  • Aspirin
  • Cilostazol
  • Dipyridamole
  • Infarct size
  • Ischemia-reperfusion injury
  • Statins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Protecting against ischemia-reperfusion injury : Antiplatelet drugs, statins, and their potential interactions. / Ye, Yumei; Perez-Polo, Jose R.; Birnbaum, Yochai.

In: Annals of the New York Academy of Sciences, Vol. 1207, 2010, p. 76-82.

Research output: Contribution to journalArticle

@article{e57765ef698c4e43b7ab673489d3b6cb,
title = "Protecting against ischemia-reperfusion injury: Antiplatelet drugs, statins, and their potential interactions",
abstract = "Statins and antiplatelet agents are currently used as therapeutic agents for patients with acute myocardial infarction. Statins limit myocardial infarct size by activating phosphatidylinositol-3-kinase (PI3K), ecto-5'-nucleotidase, Akt/endothelial nitric oxide synthase (eNOS), and the downstream effectors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Inhibition of PI3K, adenosine receptors, eNOS, iNOS, or COX-2 abrogates the protective effects of statins. At >5 mg/kg, aspirin attenuates the myocardial infarct-size-limiting effect of statins. In contrast, the combination of low-dose atoravastatin with either the phosphodiesterase-III inhibitor cilostazol or the adenosine reuptake inhibitor dipyridamole synergistically limits infarct size. Low-dose aspirin with dipyridamole started during ischemia augmented the infarct-size-limiting effects of simvastatin. In contrast, high-dose aspirin blocked the protective effect of simvastatin. The combination of dipyridamole with low-dose aspirin and simvastatin resulted in the smallest infarct size. According to themost current data available, we believe that antiplatelet regimens may require modification for patients who are receiving statins.",
keywords = "Antiplatelet agents, Aspirin, Cilostazol, Dipyridamole, Infarct size, Ischemia-reperfusion injury, Statins",
author = "Yumei Ye and Perez-Polo, {Jose R.} and Yochai Birnbaum",
year = "2010",
doi = "10.1111/j.1749-6632.2010.05725.x",
language = "English (US)",
volume = "1207",
pages = "76--82",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Protecting against ischemia-reperfusion injury

T2 - Antiplatelet drugs, statins, and their potential interactions

AU - Ye, Yumei

AU - Perez-Polo, Jose R.

AU - Birnbaum, Yochai

PY - 2010

Y1 - 2010

N2 - Statins and antiplatelet agents are currently used as therapeutic agents for patients with acute myocardial infarction. Statins limit myocardial infarct size by activating phosphatidylinositol-3-kinase (PI3K), ecto-5'-nucleotidase, Akt/endothelial nitric oxide synthase (eNOS), and the downstream effectors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Inhibition of PI3K, adenosine receptors, eNOS, iNOS, or COX-2 abrogates the protective effects of statins. At >5 mg/kg, aspirin attenuates the myocardial infarct-size-limiting effect of statins. In contrast, the combination of low-dose atoravastatin with either the phosphodiesterase-III inhibitor cilostazol or the adenosine reuptake inhibitor dipyridamole synergistically limits infarct size. Low-dose aspirin with dipyridamole started during ischemia augmented the infarct-size-limiting effects of simvastatin. In contrast, high-dose aspirin blocked the protective effect of simvastatin. The combination of dipyridamole with low-dose aspirin and simvastatin resulted in the smallest infarct size. According to themost current data available, we believe that antiplatelet regimens may require modification for patients who are receiving statins.

AB - Statins and antiplatelet agents are currently used as therapeutic agents for patients with acute myocardial infarction. Statins limit myocardial infarct size by activating phosphatidylinositol-3-kinase (PI3K), ecto-5'-nucleotidase, Akt/endothelial nitric oxide synthase (eNOS), and the downstream effectors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Inhibition of PI3K, adenosine receptors, eNOS, iNOS, or COX-2 abrogates the protective effects of statins. At >5 mg/kg, aspirin attenuates the myocardial infarct-size-limiting effect of statins. In contrast, the combination of low-dose atoravastatin with either the phosphodiesterase-III inhibitor cilostazol or the adenosine reuptake inhibitor dipyridamole synergistically limits infarct size. Low-dose aspirin with dipyridamole started during ischemia augmented the infarct-size-limiting effects of simvastatin. In contrast, high-dose aspirin blocked the protective effect of simvastatin. The combination of dipyridamole with low-dose aspirin and simvastatin resulted in the smallest infarct size. According to themost current data available, we believe that antiplatelet regimens may require modification for patients who are receiving statins.

KW - Antiplatelet agents

KW - Aspirin

KW - Cilostazol

KW - Dipyridamole

KW - Infarct size

KW - Ischemia-reperfusion injury

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=78149267940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149267940&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2010.05725.x

DO - 10.1111/j.1749-6632.2010.05725.x

M3 - Article

VL - 1207

SP - 76

EP - 82

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -